StocktoriabioAffinity Technologies, Inc. BIAF
Nasdaq · XNAS · stock · Services-Commercial Physical & Biological Research
Chart by TradingView
3/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $6.2M | $9.4M | $2.5M | $6.9M | — |
| Gross profit | — | — | — | $4,336 | — |
| Operating income | -$10.6M | -$9.0M | -$8.0M | -$4.0M | -$2.2M |
| Net income | -$14.9M | -$9.0M | -$7.9M | -$8.2M | -$6.3M |
| Operating cash flow | -$9.3M | -$7.3M | -$6.0M | -$4.1M | -$2.0M |
| Free cash flow | -$9.4M | -$7.3M | -$6.1M | -$4.3M | — |
| Total assets | $11.0M | $6.5M | $8.2M | $12.2M | $1.5M |
| Total liabilities | $3.7M | $3.9M | $3.4M | $1.1M | $13.2M |
| Shareholders' equity | $7.3M | $2.6M | $4.9M | $11.0M | -$15.8M |
| Ratios | |||||
| Gross margin | — | — | — | 0.1% | — |
| Operating margin | -171.6% | -95.6% | -314.8% | -58.1% | — |
| Net margin | -242.0% | -96.6% | -313.4% | -118.2% | — |
| FCF margin | -152.4% | -78.4% | -239.3% | -62.2% | — |
| Return on assets | -136.0% | -138.8% | -96.5% | -66.9% | -435.3% |
| Return on equity | -204.9% | -347.4% | -163.5% | -73.8% | 40.1% |
| Current ratio | 2.60 | 0.87 | 1.77 | 10.50 | 0.11 |
| Revenue growth | -34.2% | 269.7% | -63.3% | — | — |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
GOOG · MSFT · META · BABA · DIS · HCA · all Services →
Source: SEC EDGAR filings · CIK 0001712762 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.